Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VRC01-class B-cell receptors (BCRs) are a specific class of immunoglobulin receptors on B cells that serve as the precursors for broadly neutralizing antibodies (bNAbs) targeting the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein (Env) (Zhou et al., 2010, Science). These receptors are defined by specific genetic and structural features, most notably the use of the IGHV1-2 germline gene and a short light-chain complementarity-determining region 3 (LCDR3) (Jardine et al., 2013, Science). This structural configuration allows the BCR to mimic the host CD4 receptor's interaction with the virus, a critical step for neutralizing diverse HIV strains. In modern vaccinology, VRC01-class BCRs are the primary focus of germline-targeting strategies, where engineered immunogens like eOD-GT8 60mer are designed to bind and activate these rare B-cell precursors (Leggat et al., 2022, Science). The therapeutic objective is to initiate a specific lineage of B-cell maturation that, through successive vaccinations, leads to the production of high-affinity bNAbs. This approach addresses the challenge of HIV's extreme diversity by focusing the immune response on highly conserved functional sites of the viral spike. Monitoring the frequency and maturation of these BCRs in clinical trials serves as a key indicator of vaccine efficacy (Dosenovic et al., 2015, Cell). Ultimately, targeting these receptors represents a paradigm shift in vaccine design, moving from empirical methods to precision molecular targeting of the immune repertoire.
Germline-targeting immunogens bind to and activate specific germline B-cell receptors to initiate the development of broadly neutralizing antibodies through somatic hypermutation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VRC01-class B-cell receptor (VRC01-class BCR) (VRC01-class BCR).